Hoffman-Zacharska Dorota, Mierzewska Hanna, Szczepanik Elżbieta, Poznański Jarosław, Mazurczak Tomasz, Jakubiuk-Tomaszuk Anna, Mądry Jacek, Kierdaszuk Anatol, Bal Jerzy
Department of Medical Genetics, Institute Mother and Child, 01-211 Warsaw, Kasprzaka 17,
Med Wieku Rozwoj. 2013 Oct-Dec;17(4):293-300.
The Pelizaeus-Merzbacher disease (PMD) is a rare X-linked recessive hypomyelination disorder caused by mutations of the proteolipid protein1 gene (PLP1). There is a spectrum of PLP1-related disorders from very severe connatal PMD, through classical PMD to mild spastic paraplegia type 2 (SPG2), with some correlation between the type of mutation and the phenotype. In general, missense mutations give rise to more severe forms of the disease, deletions and null mutations to mild PMD and SPG2. The most common variations, duplications, result in the classical-intermediate form of PMD.
To report the analysis of mutations in the PLP1 gene and phenotype di!erences in ten male patients diagnosed with PMD. Although they had different types of PLP1 mutations (duplications, missense and nonsense mutations), all of them were clinically classi"ed with the classical form of PMD (clPMD).
The subjects of analysis were ten male patients aged 1.5 to 21 years who were diagnosed with PMD. All patients developed the "rst clinical symptoms between 1 an 8 months of age and showed developmental delay, mainly in motor skills. All were classified with the classical form of the disease, according to international clinical criteria and the electrophysiological and brain MRI criteria of hypomyelination. The molecular analysis of the PLP1 gene involved dosage analysis and direct sequencing of all exons and promotor region of the gene.
The clinical diagnosis of PMD was con"rmed for all subjects by molecular analysis of the PLP1gene. Although all had the classical form of PMD, it was caused by mutations of di!erent types: duplications of the entire gene, missense and nonsense mutations.
Our clinical and molecular "ndings showed that the phenotypic spectrum resulting from PLP1 mutations seems to be broader in patients with the PLP1 gene duplication compared to patients with both nonsense and missense mutation. Nevertheless, apart from the type of mutation, all our patients’ clinical manifestation falls into the category of the classical form of PMD according to international criteria. Obviously the type of mutations, but also other unidentified factors may a!ect the clinical course of PMD.The Pelizaeus-Merzbacher disease (PMD) is a rare X-linked recessive hypomyelination disorder caused by mutations of the proteolipid protein 1 gene (PLP1). There is a spectrum of PLP1-related disorders from very severe connatal PMD, through classical PMD to mild spastic paraplegia type 2 (SPG2), with some correlation between the type of mutation and the phenotype. In general, missense mutations give rise to more severe forms of the disease, deletions and null mutations to mild PMD and SPG2. The most common variations, duplications, result in the classical-intermediate form of PMD.
To report the analysis of mutations in the PLP1 gene and phenotype differences in ten male patients diagnosed with PMD. Although they had di!erent types of PLP1 mutations (duplications, missense and nonsense mutations), all of them were clinically classi"ed with the classical form of PMD (clPMD).
The subjects of analysis were ten male patients aged 1.5 to 21 years who were diagnosed with PMD. All patients developed the "rst clinical symptoms between 1 an 8 months of age and showed developmental delay, mainly in motor skills. All were classified with the classical form of the disease, according to international clinical criteria and the electrophysiological and brain MRI criteria of hypomyelination. The molecular analysis of the PLP1 gene involved dosage analysis and direct sequencing of all exons and promotor region of the gene.
The clinical diagnosis of PMD was con"rmed for all subjects by molecular analysis of the PLP1 gene. Although all had the classical form of PMD, it was caused by mutations of di!erent types: duplications of the entire gene, missense and nonsense mutations.
Our clinical and molecular findings showed that the phenotypic spectrum resulting from PLP1 mutations seems to be broader in patients with the PLP1 gene duplication compared to patients with both nonsense and missense mutation. Nevertheless, apart from the type of mutation, all our patients' clinical manifestation falls into the category of the classical form of PMD according to international criteria. Obviously the type of mutations, but also other unidentified factors may a!ect the clinical course of PMD.
佩利措伊斯-梅茨巴赫病(PMD)是一种罕见的X连锁隐性髓鞘形成障碍疾病,由蛋白脂质蛋白1基因(PLP1)突变引起。存在一系列与PLP1相关的疾病,从非常严重的先天性PMD,到经典型PMD,再到轻度痉挛性截瘫2型(SPG2),突变类型与表型之间存在一定相关性。一般来说,错义突变会导致更严重的疾病形式,缺失和无效突变导致轻度PMD和SPG2。最常见的变异,即重复,会导致经典-中间型PMD。
报告对10例诊断为PMD的男性患者的PLP1基因突变分析及表型差异。尽管他们有不同类型的PLP1突变(重复、错义突变和无义突变),但他们在临床上均被归类为经典型PMD(clPMD)。
分析对象为10例年龄在1.5至21岁之间诊断为PMD的男性患者。所有患者在1至8个月大时出现首次临床症状,并表现出发育迟缓,主要是运动技能方面。根据国际临床标准以及髓鞘形成减少的电生理和脑MRI标准,所有患者均被归类为经典型疾病。PLP1基因的分子分析包括剂量分析以及对该基因所有外显子和启动子区域的直接测序。
通过PLP1基因的分子分析,所有受试者的PMD临床诊断均得到证实。尽管所有患者均为经典型PMD,但病因是不同类型的突变:整个基因的重复、错义突变和无义突变。
我们的临床和分子研究结果表明,与有无义突变和错义突变的患者相比,PLP1基因重复的患者中PLP1突变导致的表型谱似乎更广泛。然而,除了突变类型外,根据国际标准,我们所有患者的临床表现都属于经典型PMD类别。显然,突变类型以及其他未确定的因素可能会影响PMD的临床病程。佩利措伊斯-梅茨巴赫病(PMD)是一种罕见的X连锁隐性髓鞘形成障碍疾病,由蛋白脂质蛋白1基因(PLP1)突变引起。存在一系列与PLP1相关的疾病,从非常严重的先天性PMD,到经典型PMD,再到轻度痉挛性截瘫2型(SPG2),突变类型与表型之间存在一定相关性。一般来说,错义突变会导致更严重的疾病形式,缺失和无效突变导致轻度PMD和SPG2。最常见的变异,即重复,会导致经典-中间型PMD。
报告对10例诊断为PMD的男性患者的PLP1基因突变分析及表型差异。尽管他们有不同类型的PLP1突变(重复、错义突变和无义突变),但他们在临床上均被归类为经典型PMD(clPMD)。
分析对象为10例年龄在1.5至21岁之间诊断为PMD的男性患者。所有患者在1至8个月大时出现首次临床症状,并表现出发育迟缓,主要是运动技能方面。根据国际临床标准以及髓鞘形成减少的电生理和脑MRI标准,所有患者均被归类为经典型疾病。PLP1基因的分子分析包括剂量分析以及对该基因所有外显子和启动子区域的直接测序。
通过PLP1基因的分子分析,所有受试者的PMD临床诊断均得到证实。尽管所有患者均为经典型PMD,但病因是不同类型的突变:整个基因的重复、错义突变和无义突变。
我们的临床和分子研究结果表明,与有无义突变和错义突变的患者相比,PLP1基因重复的患者中PLP1突变导致의表型谱似乎更广泛。然而,除了突变类型外,根据国际标准,我们所有患者의临床表现都属于经典型PMD类别。显然,突变类型以及其他未确定의因素可能会影响PMD의临床病程。